Abstract
To the Editor: Bruton tyrosine kinase (BTK) inhibitors have greatly improved the spectrum of treatment options in mantle cell lymphoma (MCL) [1–4]. Acalabrutinib is a highly selective, orally administered, and potent BTK inhibitor with limited off-target activity [5]. Acalabrutinib was approved in 2017 by the US Food and Drug Administration for the treatment of relapsed/refractory MCL based on clinical data from the open-label, multicenter, phase 2 ACE-LY-004 study of acalabrutinib 100 mg twice daily [1]. Here, we present updated results from the ACE-LY-004 study after a median 26-month follow-up. Eligibility criteria and study design were published previously (Supplementary methods) [1]. Analysis of minimal residual disease (MRD) was conducted after complete response (CR) or partial response (PR) was achieved using the quantitative ClonoSEQ next-generation sequencing (5 × 10-6) assay (Adpative Biotechnologies, Seattle, WA, USA) in consenting patients with available paired archival tumor and whole blood samples. Data are updated as of February 12, 2018.
DOI
10.1038/s41375-019-0575-9
Publication Date
2019-09-26
Publication Title
Leukemia
Volume
33
Issue
11
Publisher
Springer Nature [academic journals on nature.com]
ISSN
1476-5551
Embargo Period
2024-11-19
First Page
2762
Last Page
2766
Recommended Citation
Wang, M., Rule, S., Zinzani, P., & et al. (2019) 'Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma', Leukemia, 33(11), pp. 2762-2766. Springer Nature [academic journals on nature.com]: Available at: https://doi.org/10.1038/s41375-019-0575-9
